INTRODUCTION {#s1}
============

Non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer \[[@R1]\], which ranks first for mortality among the malignant neoplasms \[[@R2]\], even with advanced chemotherapy and precise molecular-targeted treatment. According to histological type, NSCLC is divided into three main categories: squamous-cell carcinoma (SCC), adenocarcinoma (ADC) and large-cell carcinoma (LCC) \[[@R3]\]. Although smoking is one of the established risk factors for NSCLC, a particular genetic alteration or genotype combination, especially the interaction of environmental factors and genes is also involved in the occurrence and development of this malignant neoplasm \[[@R4]--[@R6]\].

MicroRNAs (miRNAs) are a large family of small endogenous non-coding RNA in the length of 21-25 nucleotides, which can modulate the expression of target messenger RNA (mRNA) by mRNA cleavage or post-transcriptional inhibition \[[@R7], [@R8]\]. Mature miRNAs are produced from the stem loop structure of precursor miRNAs (pre-miRNAs) derived from a long primary miRNA (pri-miRNA) \[[@R9]\]. In terms of all the gene sequence, miRNAs are more likely to produce a single gene mutation \[[@R10]\]. Emerging in the pri-miRNAs, the single nucleotide polymorphisms (SNPs) influences the maturation of respective miRNAs, which then affects its mature miRNAs expression and interaction as a consequence \[[@R11]--[@R13]\]. In the field of NSCLC, SNPs in the pri-miRNAs may prognosticate the development of cancer susceptibility and prognosis as genetic detection markers \[[@R14]\].

Hsa-miR-219a-1 (miR-219-1), located on chromosome 6 (6p21), may exert an influence on lung cancer \[[@R15], [@R16]\]. Several SNPs in the pri-miRNA sequence of miR-219-1 have been recognized and studied, of which rs213210 was associated with poor prognosis in colorectal cancer \[[@R17]\], rs107822 reduced the risk of esophageal cancer \[[@R18]\], and rs421446 was correlated to the risk of hepatocellular carcinoma progression \[[@R19]\]. Given the linkage disequilibrium of these three loci has been reported and verified, we propose a hypothesis in the present study: rs213210, rs421446 and rs107822 in miR-219-1, as a SNP or a haplotype, may be related to NSCLC susceptibility and prognosis.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

The demographic characteristics of 405 cases and 405 controls in the present study are summarized in Table [1](#T1){ref-type="table"}. There was no significant difference in the distributions of age (*P*=0.49) between the cases (51.27±22.08 years) and controls (50.23±21.02 years). While, the distributions of gender and smoking status were of significant differences (both were *P*\<0.001), so the next study was adjusted by smoking status, age and gender. Among 405 patients there were 324 subjects have follow-up information, with the median follow-up time was 24.35 months.

###### Demographics of NSCLC patients and controls

                             Cases         Controls      *P*-value
  -------------- ----------- ------------- ------------- -----------
  Gender         male        256(64.6)     140(35.4)     
                 female      149(36.0)     265(64.0)     \<0.001
  Age(years)     mean±SD     51.27±22.08   50.23±21.02   0.49
  Smoke          never       310(76.5)     357(88.1)     
                 yes         95(23.4)      48(11.9)      \<0.001
  Histology      ADC         261(80.5)                   
                 SCC         69(21.3)                    
                 LCC         10(3.1)                     
                 unknown     65(20.1)                    
  Chemo          no          6(1.8)                      
                 yes         297(91.7)                   
                 unknown     21(6.5)                     
  Surgical       No          90(27.8)                    
                 yes         226(69.7)                   
                 unknown     8(2.5)                      
  Clinic stage   IA+IB       128(40.5)                   
                 IIA+IIB     77(24.8)                    
                 IIIC+IIID   58(17.9)                    
                 IV          61(18.8)                    
  Time(months)   mean±SD     24.35±18.70                 
  Status         alive       65(20.0)                    
                 dead        259(80.0)                   

pri-miR-219-1 polymorphisms are associated with the risk for NSCLC {#s2_2}
------------------------------------------------------------------

Table [2](#T2){ref-type="table"} described genotype and allele distributions of rs213210 T\>C, rs421446 C\>T and rs107822 A\>G in cases and controls. The observed genotype frequencies for three SNPs in the control were conformed to Hardy-Weinberg equilibrium (*P*\>0.05). The minor allele frequencies (MAF) of rs213210, rs421446 and rs107822 were 0.42, 0.40 and 0.47, respectively. Both CC genotype carriers (adjusted OR=3.462, 95%CI=2.222-5.394, *P*\<0.001) compared with TT genotype carriers in rs231210 and GG genotype carriers (adjusted OR=3.553, 95%CI=2.329-5.419, *P*\<0.001) compared with AA genotype carriers in rs107822 demonstrated more increased risk of NSCLC. The results of stratified analysis by gender and smoking status showed in [Supplementary Tables 1 and 2](#SD1){ref-type="supplementary-material"}.

###### Distribution of pri-miR-219-1 rs213210, rs421446 and rs107822 genotypes and ORs for NSCLC cases and controls

  Genotype    Cases   Controls   *P*-value   OR      95%CI            *P* adj   OR adj   95%CI adj
  ----------- ------- ---------- ----------- ------- ---------------- --------- -------- ----------------
  rs213210                                                                               
   TT         113     160        \<0.001                              \<0.001            
   CT         194     191        0.023       1.438   (1.052, 1.967)   0.057     1.383    (0.990, 1.932)
   CC         98      54         \<0.001     2.570   (1.705, 3.873)   \<0.001   3.462    (2.222, 5.394)
   TT         113     160                                                                
   CT+CC      292     245        0.001       1.688   (1.257, 2.266)   \<0.001   1.779    (1.301, 2.432)
   TT+CT      307     351                                                                
   CC         98      54         \<0.001     2.075   (1.439, 2.991)   \<0.001   2.874    (1.930, 4.279)
   T allele   420     511                                                                
   C allele   390     299        \<0.001     1.587   (1.301,1.935)    \<0.001   1.792    (1.449, 2.216)
  rs421446                                                                               
   CC         129     174        0.004                                0.040              
   TC         198     170        0.004       1.571   (1.156, 2.134)   0.017     1.485    (1.075, 2.051)
   TT         78      61         0.008       1.725   (1.150, 2.586)   0.079     1.469    (0.956, 2.258)
   CC         129     174                                                                
   CT+TT      276     231        0.001       1.602   (1.202, 2.136)   0.522     0.920    (0.712, 1.188)
   CC+CT      327     344                                                                
   TT         78      61         0.165       1.295   (0.899, 1.865)   0.012     1.475    (1.089, 1.997)
   C allele   456     518                                                                
   T allele   354     292        0.002       1.377   (1.128,1.681)    0.026     1.272    (1.030, 1.572)
  rs107822                                                                               
   AA         79      162        \<0.001                              \<0.001            
   GA         206     174        \<0.001     2.428   (1.735, 3.398)   \<0.001   2.376    (1.664, 3.392)
   GG         120     69         \<0.001     3.566   (2.391, 5.320)   \<0.001   3.553    (2.329, 5.419)
   AA         79      162                                                                
   GA+GG      326     243        \<0.001     2.751   (2.005, 3.774)   \<0.001   2.711    (1.941, 3.788)
   AA+GA      285     336                                                                
   GG         120     69         \<0.001     2.050   (1.466, 2.868)   \<0.001   2.074    (1.455, 2.957)
   G allele   446     312                                                                
   A allele   364     498        \<0.001     4.026   (3.251, 4.985)   \<0.001   1.952    (1.582, 2.407)

*P*~adj~ is adjusted by smoking, age and gender.

Interactions between polymorphisms of pri-miR-219-1 and tobacco exposure {#s2_3}
------------------------------------------------------------------------

This study further investigated the interaction of tobacco exposure and SNPs in cross-over analysis (Table [3](#T3){ref-type="table"}). Relative to rs213210 non-smoking and TT genotype carriers, the OR (4.33) for CC genotype carriers with tobacco exposure was higher than the OR (2.45) for rs213210 TT carriers with tobacco exposure or the OR (3.83) for rs213210 CC genotype carriers without tobacco exposure. Similar results were obtained when rs421446- and rs107822-tobacco exposure were examined. Above cross-over results indicated that SNPs-tobacco exposure interaction may exist, therefore statistical tests were used to evaluate the significance of the interaction on both additive scale and multiplicative scale (data not shown). The results suggested that interactions between the SNPs and tobacco exposure were not significant on an additive scale or a multiplicative scale.

###### Interaction of pri-miR-219-1 variants and tobacco exposure on NSCLC

  Genotype   Smoking   Cases   Controls   *P*-value   OR(95% CI)          *P*-value adj.   OR(95% CI) adj.
  ---------- --------- ------- ---------- ----------- ------------------- ---------------- -------------------
  rs213210                                                                                 
   TT        \-        88      138        \<0.001                         \<0.001          
   CT        \-        140     173        0.180       1.27(0.90, 1.80)    0.199            1.27(0.88, 1.84)
   CC        \-        82      46         \<0.001     2.80(1.78, 4.38)    \<0.001          3.83(2.37, 6.20)
   TT        \+        25      22         0.073       1.78(0.95, 3.35)    0.009            2.45(1.25, 4.81)
   CT        \+        54      18         \<0.001     4.71(2.59, 8.54)    \<0.001          5.15(2.74, 9.67)
   CC        \+        16      8          0.012       3.14(1.29, 7.64)    0.002            4.33(1.70, 11.06)
  rs421446                                                                                 
   CC        \-        109     150        \<0.001                         \<0.001          
   TC        \-        148     154        0.101       1.32(0.95, 1.85)    0.179            1.27(0.90, 1.80)
   TT        \-        53      53         0.168       1.38(0.87, 2.17)    0.358            1.25(0.78, 2.01)
   CC        \+        20      24         0.676       1.15(0.60, 2.18)    0.453            1.30(0.66, 2.55)
   TC        \+        50      16         \<0.001     4.30(2.33, 7.95)    \<0.001          4.65(2.45, 8.82)
   TT        \+        25      8          0.001       4.30(1.87, 9.90)    0.001            4.30(1.81, 10.24)
  rs107822                                                                                 
   AA        \-        65      147        \<0.001                         \<0.001          
   GA        \-        151     151        \<0.001     2.26(1.56, 3.27)    \<0.001          2.32(1.58, 3.42)
   GG        \-        94      59         \<0.001     3.60(2.33, 5.58)    \<0.001          3.64(2.30, 5.75)
   AA        \+        14      15         0.062       2.11(0.96, 4.63)    0.050            2.28(1.00, 5.22)
   GA        \+        55      23         \<0.001     5.41(3.07, 9.54)    \<0.001          6.06(3.33, 11.03)
   GG        \+        26      10         \<0.001     5.88(2.68, 12.90)   \<0.001          7.24(3.19, 16.44)

*P*-value adj. is adjusted by age and gender.

Haplotype association analysis of SNPs on pri-miR-219-1 {#s2_4}
-------------------------------------------------------

The LD of rs213210, rs421446 and rs107822 was observed in Ensemble variation resources \[[@R20]\], each of them suggested great LD in pri-miR-219-1 of NSCLC (all D=1 and r^2^\>0.5). The haplotype analysis of miR-219 SNPs was performed using online software SHEsis (<http://analysis.bio-x.cn>). Figure [1](#F1){ref-type="fig"} intuitively represented the odd ratio of the dangerous and protective haplotype symbolized by the pie area. Each pie represented a haplotype, plotted by cases on horizontal axis, controls on vertical axis. Red pies meant dangerous haplotypes, blue pies meant protective haplotypes, and grey pies meant that distribution of these haplotypes was of no significant difference between cases and controls. The biggest red pie presented the risk of individual carrying C~rs213210~C~rs421446~G~rs107822~ was significantly higher than all other haplotypes (OR=4.997, 95%CI= 3.524-7.086, *P*\<0.001) (Table [4](#T4){ref-type="table"}).

![Distribution of haplotypes in cases and controls\
(1) The area of the pie represents the odd ratio (take the inverse when OR \< 1). (2) Red pies present dangerous type, the blue ones are protectors, grey pie means no statistical significance different. (3) The axis represents the number of subjects.](oncotarget-08-56533-g001){#F1}

###### Association analysis of rs213210, rs421446 and rs107822 on the pri-miR-219-1 with risk of NSCLC

  Haplotype   Cases (%)   Controls (%)   *P*-value   OR (95%CI)
  ----------- ----------- -------------- ----------- ----------------------
  C C A       73 (9.0)    145(17.9)      \<0.001     0.456 (0.338, 0.615)
  C C G       177(21.9)   43(5.3)        \<0.001     4.997 (3.524, 7.086)
  C T A       70(8.7)     80(9.9)        0.403       0.867 (0.620, 1.212)
  C T G       68(8.5)     30(3.7)        \<0.001     2.379 (1.533, 3.693)
  T C A       83(10.4)    274(33.9)      \<0.001     0.225 (0.172, 0.295)
  T C G       121(15.0)   54(6.8)        \<0.001     2.419 (1.730, 3.382)
  T T A       135(16.8)   120(14.9)      0.291       1.155 (0.884, 1.509)
  T T G       78(9.7)     60(7.5)        0.109       1.330 (0.937, 1.887)

Evaluated the effects of pri-miR-219-1 SNPs in NSCLC clinical outcome {#s2_5}
---------------------------------------------------------------------

Table [5](#T5){ref-type="table"} rendered the results using multivariate Cox model for investigating the association between genotype polymorphisms in pri-miR-219 and NSCLC prognosis, adjusted for smoking status, age and gender. There was no relationship between rs213210, rs421446 or rs107822 polymorphisms and prognosis of OS in this study.

###### pri-miR-219-1 SNPs associated with outcomes of NSCLC patients and stratified by stages

  Genotype       Cases   *P*-value   HR      95%CI            *P*-value adj   HR adj   95%CI adj
  -------------- ------- ----------- ------- ---------------- --------------- -------- ----------------
  rs213210                                                                             
   TT            85      0.235                                0.154                    
   CT            148     0.093       1.298   (0.957, 1.760)   0.063           1.344    (0.984, 1.836)
   CC            91      0.224       1.236   (0.879, 1.737)   0.120           1.330    (0.928, 1.905)
  Stage I+II                                                                           
   T allele      206                                                                   
   C allele      204     0.114       0.838   (0.673, 1.043)   0.184           0.860    (0.678, 1.075)
  Stage III+IV                                                                         
   T allele      112                                                                   
   C allele      126     0.047       1.365   (1.004, 1.855)   0.065           1.358    (0.981, 1.878)
  rs421446                                                                             
   CC            110     0.358                                0.413                    
   TC            151     0.152       0.818   (0.622, 1.077)   0.185           0.829    (0.627, 1.094)
   TT            63      0.477       0.880   (0.617, 1.253)   0.482           0.878    (0.611, 1.261)
  Stage I+II                                                                           
   C allele      235                                                                   
   T allele      175     0.310       0.892   (0.714, 1.113)   0.199           0.864    (0.692, 1.080)
  Stage III+IV                                                                         
   C allele      136                                                                   
   T allele      102     0.102       0.775   (0.572, 1.051)   0.147           0.795    (0.582, 1.084)
  rs107822                                                                             
   AA            66      0.147                                0.139                    
   GA            159     0.693       1.066   (0.776, 1.465)   0.536           1.107    (0.803, 1.526)
   GG            99      0.084       1.355   (0.960, 1.913)   0.065           1.384    (0.980, 1.955)
  Stage I+II                                                                           
   A allele      192                                                                   
   G allele      217     0.054       1.243   (0.996, 1.552)   0.057           1.241    (0.994, 1.549)
  Stage III+IV                                                                         
   A allele      99                                                                    
   G allele      140     0.895       0.980   (0.724, 1.326)   0.930           0.987    (0.729, 1.336)

*P*~adj~ is adjusted by smoking, age and gender.

DISCUSSION {#s3}
==========

The occurrence and development of NSCLC is a complicated process, which is inevitably affected by multiple established or uncertain factors. In recent years, researchers all around world have made great efforts to elucidate microRNAs' functions in initiation and progression of lung cancer. Recent studies showed that expression level of miRNAs in cells from cancer tissue were often in deregulation compared with adjacent normal tissues \[[@R13], [@R21]\]. An early group has suggested that miR-219 was significantly downregulated in hepatocellular carcinoma, also exerted tumor-suppressive effects in hepatic carcinogenesis via inhibiting transcription and translation of glypican-3 \[[@R22]\].

SNPs in microRNAs non-coding region may affect Drosha or Dicer trimming or reshaping miRNA target genes. A previous study on esophageal squamous cell carcinoma in Chinese Kazakh demonstrated that rs107822 A allele in primary form of miR-219-1 may reduce the efficacy of the maturation process from pre-mir-219-1 to miR-219-1 compared with G allele \[[@R18]\].

On the whole, the present research firstly reported association between the polymorphisms in miR-219-1 (rs213210, rs421446 and rs107822) and susceptibility or prognosis of NSCLC. In our study, after Bonferroni correction, CC genotype carriers of rs213210, as well as GG and GA genotypes carriers of rs107822 were still significantly dangerous for risk of lung cancer, compared with other genotypes. A previous study reported that rs107822 was associated with risk of esophageal squamous cell carcinoma in Chinese Kazakh \[[@R18]\], moreover, this locus also influenced susceptibility of schizophrenia via N-Methyl-D-aspartate-type glutamate receptor signaling pathway \[[@R23], [@R24]\]. Taken together, these results suggested that rs107822 polymorphism may play a considerable role in the process of cancer development.

Given that smoking is an established major environmental risk for developing lung cancer, gene-environment interactions may have potential effect. An early study to evaluate the lungs of environmental cigarette smoke-exposed mice showed that expression level of miR-219-1-5p was significantly low compared with normal mice \[[@R25]\]. The effects of interaction between polymorphisms in miR-219-1 and tobacco exposure on lung cancer have seldom been investigated. Hence, in our study, we evaluated the interaction between smoking status and three miRNA SNPs by using cross-over analysis. We found that tobacco exposure and SNPs interaction may exist, however, not significant in an additive scale or a multiplicative scale.

Haplotypes are more meaningful than a single SNP for changes in gene function \[[@R26], [@R27]\]. We found that C~rs213210~ C~rs421446~G~rs107822~ haplotype among 5 common haplotypes in our study was most dangerous than any other haplotypes. However, SNPs and haplotypes of miR-219-1 with susceptibility to lung cancer should be investigated in further studies with a larger size of samples.

In Cox model, there were no significant associations between the polymorphism in miR-219-1 (rs213210, rs421446 and rs107822) and survival of NSCLC patients. Results of rs213210 were consistent with those from a previous study \[[@R14]\]. But in stage III of colorectal cancer, C allele carriers in rs213210 were significantly related with a better outcome \[[@R28]\].

Although we still cannot fully understand the mechanism of NSCLC, it is needless to say the importance of research that SNPs affect susceptibility and prognosis of NSCLC. Considering the temporality of epigenetic change and diverse distribution of miR-219-1 in human body, there could be differences in the distribution of SNPs loci between tissues and blood. Although statistical power is 87% in our study, a larger sample size is required to verify the relation of rs213210, rs421446 or rs107822 polymorphisms with the mechanism of lung cancer in the further study.

MATERIALS AND METHODS {#s4}
=====================

Subject data collection {#s4_1}
-----------------------

Our hospital-based case control study population consisted of 405 NSCLC patients and 405 cancer-free controls. Cases were firstly diagnosed as NSCLC by the professional pathologists without restriction of gender or histology. Meanwhile, control subjects as frequency-matched cases according to age (±5 years) were individuals with other type of diseases, such as gastritis, coronary disease, diabetes mellitus and so on. The whole subjects were recruited from unrelated ethnic Han Chinese, with at least two years of follow-up time, in the Fourth Affiliated Hospital of China Medical University. Our study was performed in full compliance with requirements of the Institutional Review Board of China Medical University. Each subject signed an informed consent form. And consent from subject\'s representative was approved if subject\'s consent could not be obtained.

The data was collected under the following strict criterions: (i) 10 ml peripheral blood was donated by each participant during their first hospitalization; (ii) Each volunteer have no history of radiotherapy or chemotherapy; (iii) Tobacco exposure (a non-smoker is defined less than 100 cigarettes consumed in his whole life, otherwise are smokers) and demographical characteristics were questioned by well-trained interviewers under a pretested questionnaire just after taking their blood; and (iv) Patient\'s pathology and medical records were reviewed by us for clinical stage, pathologic type, date of diagnosis and performance status, twice a year.

DNA genotyping {#s4_2}
--------------

Genomic DNA samples were extracted from proteinase K-digested leukocyte pellet by conventional phenol--chloroform extraction and ethanol precipitation method \[[@R29]\]. SNP Genotyping was done using Taqman allelic discrimination assay from Applied Biosystems (ABI, Foster City, CA). The SNP Assays were also purchased from ABI, including primer and FAM/VIC probe (assay ID C_2215074_10 for rs213210, C_27015692_10 for rs421446 and C_2215075_20 for rs107822). Each reaction in Fast 96-well plate was conducted in a total volume of 10 μL including 2 μL purified genomic DNA (15--25 ng/μL), 5 μL TaqMan Genotyping master mix, 2.5 μL RNase-free water and 0.5 μL SNP Assay. The quantitative real-time PCR (qPCR) condition was as follows: 95°C for 10 min, followed by 47 cycles of 30 secs at 92°C, and 1 min at 62°C. The reacted results were read by an ABI 7500 FAST Real-Time PCR System with the Sequence Detection Software. A 5% selected sample were duplicated to validate the results, which were 100% consistent.

Statistical analysis {#s4_3}
--------------------

The χ2 test and Student\'s *t*-test were used to examine difference between cases and controls in demographic variables, tobacco exposure and SNPs of genotypes. Hardy--Weinberg equilibrium (HWE) \[[@R30]\] of each SNP was tested by Pearson\'s goodness-of-fit test among control. Logistic regression model and Cox\'s proportional hazards model were used to estimate the odds ratios (ORs) and hazard ratios (HRs) and their 95% confidence intervals (CIs) for unconditional logistic regression analysis and the multivariate survival analyses, respectively. Crossover analysis was applied to examine gene-environment interactions. All the analyses were adjusted by age and gender. Linkage disequilibrium (LD) was measured in Haploview algorithm \[[@R31]\], haplotype analysis were performed by using SHEsis Software \[[@R32]\]. All above analyses were two-sided, and performed in Statistical Products and Services Solutions software (v.16.0, SPSS Institute Cary, Chicago, IL, USA) unless specified. A value of *P*\< 0.05 was considered statistical significant.

CONCLUSION {#s5}
==========

There may exist significant association between polymorphisms in miR-219-1 (rs213210 and rs107822) and lung cancer risk in Chinses population. There is no relationship between polymorphisms in miR-219-1 (rs213210, rs421446 and rs107822) and outcome of lung cancer.

SUPPLEMENTARY MATERIALS TABLES {#s6}
==============================
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